Efficacy and Tolerability of Tegoprazan Compared to Proton Pump Inhibitors in the Treatment of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
ABSTRACT Aim Tegoprazan, a potassium‐competitive acid blocker, is an acid‐suppressing medication under review as a potential alternative treatment in cases of erosive esophagitis. This systematic review and meta‐analysis assesses the efficacy and tolerability of tegoprazan compared to proton pump inhibitors, the current standard of care. Methods Pubmed, Cochrane Library, Web of Science, Scopus, Embase, and Medline Ovid were systematically searched for articles up to November 25, 2025. Inclusion criteria selected RCTs that included patients with erosive esophagitis and studies of safety and efficacy, while exclusion criteria were defined by nonhuman studies, healthy patient populations, Helicobacter pylori ‐positive populations, and non‐RCT publication types. This review was registered with PROSPERO (CRD42024602209). Results Out of 724 screened studies, 5 RCTs were selected for this review, with a total of 1386 patients. Tegoprazan efficacy outcomes were consistent with non‐inferiority when compared to PPIs in the healing of erosive esophagitis (risk ratio: 1.03, 95% confidence interval: 1.00–1.07), as confirmed endoscopically. Comparable tolerability was also demonstrated (rate ratio: 0.97, 95% confidence interval: 0.68–1.37), with a similar distribution of treatment‐emergent adverse events across treatment groups. Conclusions Tegoprazan was non‐inferior to PPIs in both efficacy and tolerability, in accordance with the definition of non‐inferiority set by the RCTs. This…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,386 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.